초록 ▼

The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting

The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.

대표청구항 ▼

1. A method for the treatment of psoriatic arthritis or inflammatory bowel disease in a subject, the method comprising administering to the subject an antibody or a functional fragment thereof that is reactive with the second extracellular loop of C5aR set forth as the amino acid sequence from resid

1. A method for the treatment of psoriatic arthritis or inflammatory bowel disease in a subject, the method comprising administering to the subject an antibody or a functional fragment thereof that is reactive with the second extracellular loop of C5aR set forth as the amino acid sequence from residue 175 to 206 of SEQ ID NO: 1. 2. A method according to claim 1, wherein the antibody or a functional fragment thereof is reactive with the same epitope of C5aR as (i) a monoclonal antibody as deposited with ECACC under accession number 00110609; or (ii) a monoclonal antibody as deposited with ECACC under accession number 02090226; or (iii) a monoclonal antibody as deposited with ECACC under accession number 04090801. 3. A method according to claim 1, wherein the antibody or a functional fragment thereof competitively inhibits the binding of (i) a monoclonal antibody as deposited with ECACC under accession number 00110609; or (ii) a monoclonal antibody as deposited with ECACC under accession number 02090226; or (iii) a monoclonal antibody as deposited with ECACC under accession number 04090801 to C5aR. 4. A method according to claim 3, wherein competitive inhibition of binding is determined by antibody-antibody competition assays in the presence of C5aR or a polypeptide comprising an extracellular loop of C5aR. 5. A method according to claim 1, wherein the antibody comprises light and heavy chain sequences comprising the amino acid sequences as set forth in SEQ ID NO:19 and SEQ ID NO:21, respectively. 6. A method according to claim 1, wherein the antibody comprises light and heavy chain sequences comprising the amino acid sequences as set forth in SEQ ID NO:15 and SEQ ID NO:17, respectively. 7. A method according to claim 1, wherein the antibody comprises light and heavy chain sequences comprising the amino acid sequences as set forth in SEQ ID NO:23 and SEQ ID NO:25, respectively. 8. A method according to claim 1, wherein the antibody also inhibits activation of neutrophils by a chemoattractant ligand other than C5a. 9. A method according to claim 1, wherein the antibody is a monoclonal, chimeric humanized or recombinant antibody. 10. A method according to claim 1, wherein the antibody is a class IgG2a or class IgG3 antibody. 11. A method according to claim 1, wherein the antibody comprises a heavy chain comprising heavy chain CDR loop sequences CDR1, CDR2 and CDR3 as shown in SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, respectively; and a light chain comprising light chain CDR loop sequences as defined by amino acid residues 24 to 39, 55 to 61 and 94 to 102 of the variable light chain sequence as shown in SEQ ID NO:19. 12. A method according to claim 1, wherein the antibody comprises a heavy chain comprising heavy chain CDR loop sequences CDR1, CDR2 and CDR3 as shown in SEQ ID NO:29, SEQ ID NO:30 and SEQ ID NO:31, respectively; and a light chain comprising light chain CDR loop sequences as defined by amino acid residues 24 to 39, 55 to 61 and 94 to 102 of the variable light chain sequence as shown in SEQ ID NO:15. 13. A method according to claim 1, wherein the antibody comprises a heavy chain comprising heavy chain CDR loop sequences CDR1, CDR2 and CDR3 as shown in SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34, respectively; and a light chain comprising light chain CDR loop sequences as defined by amino acid residues 24 to 39, 55 to 61 and 94 to 102 of the variable light chain sequence as shown in SEQ ID NO:23. 14. A method according to claim 1, wherein the antibody comprises a light chain comprising the amino acid sequence as set forth in SEQ ID NO:19. 15. A method according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:21. 16. A method according to claim 1, wherein the antibody comprises a light chain comprising the amino acid sequence as set forth in SEQ ID NO:15. 17. A method according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:17. 18. A method according to claim 1, wherein the antibody comprises a light chain comprising the amino acid sequence as set forth in SEQ ID NO:23. 19. A method according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:25, wherein the antibody binds to C5aR and reduces or inhibits the binding of C5a to C5aR. 20. A method according to claim 1, wherein the antibody or functional fragment thereof is a whole antibody. 21. A method according to claim 1, wherein the antibody or functional fragment thereof reduces or inhibits the binding of C5a to C5aR.